IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

Drug & research development » Clinical trials » NCT00004806

Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis

Official title: Not provided

Clinical Trials gov number: NCT00004806

Click on the tabs to move through the sequence.

Purpose: To evaluate the efficacy and safety of lipid-mediated transfer of the CF transmembrane conductance regulator gene to nasal epithelium in CF patients

Phase: 1

Type: Interventional

Study sponsor: University of Alabama at Birmingham; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

      • Sweat chloride >60 mEq/L
      • Clinical manifestations of CF
      • Homozygous delta F508 mutation preferred
      • Compound heterozygotes for F508 mutation with pancreatic insufficiency eligible
      • FEV1 >40% of predicted PO2 ≥60 mm Hg on room air
      • No acute or recurrent sinusitis
      • No obstructive nasal polyposis
      • No pneumothorax or hemoptysis, e.g., >250 mL blood within 24-hour period, within past year
      • No unstable lung disease with worsening pulmonary symptoms, arterial blood gas, or pulmonary function tests within 2 weeks prior to entry
      • No pulmonary exacerbation within 4 weeks prior to entry

Prior/Concurrent Therapy

      • ≥2 months since participation in any other clinical study
      • ≥2 months since DNase
      • ≥4 months since corticosteroids

Patient Characteristics

    • Cardiac: No severe cardiac disease
    • Other: No other severe organ system disease, e.g., juvenile-type diabetes mellitus
    • No pregnant women

Intervention
Genetic

Geographical Location
No contacts or locations provided

Number of Participants
≤50 (≥18 years)

Primary Endpoint

Not provided

Secondary Endpoint

Not provided

Click on the tabs to move through the sequence.

Not provided

View Trial Results